Market Cap 2.00M
Revenue (ttm) 0.00
Net Income (ttm) -19.39M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio -4.19
Volume 74,200
Avg Vol 4,816,526
Day's Range N/A - N/A
Shares Out 6.26M
Stochastic %K 16%
Beta 0.77
Analysts Strong Buy
Price Target N/A

Company Profile

GlucoTrack, Inc., a medical device company, focuses on the development of an implantable continuous blood glucose monitor (CBGM) for people with diabetes in the United States. The company develops the GlucoTrack CBGM, a long-term implantable blood-based CBGM for use by Type 1 diabetes patients and insulin-dependent Type 2 diabetes patients. The company was formerly known as Integrity Applications, Inc. and changed its name to GlucoTrack, Inc. in November 2021. GlucoTrack, Inc. was founded in 200...

Industry: Medical Instruments & Supplies
Sector: Healthcare
Phone: 201 842 7715
Address:
301 Route 17 North, Suite 800, Rutherford, United States
CallMeMyBeer
CallMeMyBeer Jul. 4 at 2:58 AM
0 · Reply
Luckyizme
Luckyizme Jul. 2 at 12:09 AM
$GCTK This is due for another big runup. This week runners, $INO, $VTGN, $PCSA
1 · Reply
MarketsParadise
MarketsParadise Jul. 1 at 8:23 PM
Small caps heating up, We are seeing some big runners lately. Take a look at ticker DRCT 💎 I believe this is the next monster runner waiting to be found: DRCT 💎 • 600K share float! • AI-powered digital advertising & marketing drive. • Extremely thin chart. • Any sustained buying pressure we look for the 5$+. $GCTK $WCT.X $WHLR $ADTX ..22
0 · Reply
tartanurchin
tartanurchin Jul. 1 at 7:50 PM
$GCTK warming up???
0 · Reply
Glucotrack_IR
Glucotrack_IR Jul. 1 at 2:49 PM
$GCTK For decades, blood glucose monitoring (BGM) has helped people with diabetes understand their glucose levels through measurements taken at specific moments in time. At the same time, diabetes technology has advanced through different approaches to continuous glucose monitoring. Yet, one question remains: what if the continuity of modern monitoring could be combined with direct blood glucose measurement? That is the idea behind our Continuous Blood Glucose Monitoring (CBGM) technology. Rather than simply improving an existing approach, we are developing a novel system designed to bring together the benefits of continuous monitoring with direct blood glucose measurement, while also addressing the limitations associated with current wearable technologies. Innovation is often driven by challenging assumptions and exploring new possibilities. That is what excites us most about CBGM and its potential to help shape the next evolution of glucose monitoring.
0 · Reply
topstockalerts
topstockalerts Jul. 1 at 11:10 AM
Pre Market Top Gainers PT2 $LGPS $LGO $CEPO $FEAM $GCTK
0 · Reply
Deerslayer1998
Deerslayer1998 Jun. 30 at 6:16 AM
$GCTK so sad. A great product needed and no real news on these seminars. Guess people aren’t liking what they are seeing. I still believe in product but not management
1 · Reply
Glucotrack_IR
Glucotrack_IR Jun. 29 at 2:12 PM
$GCTK Diabetes affects roughly 1 in every 9 adults globally, including more than 38 million people in the United States alone, making it one of the most significant and widespread healthcare challenges of our time. Regardless of treatment strategy, medication, or insulin regimen, diabetes therapy often begins with one thing: understanding glucose levels. The information generated through glucose monitoring helps guide countless decisions made by people living with diabetes and healthcare providers every day. As a result, advances in how glucose is monitored measured have the potential to shape the broader standard of care. Meaningful advances begin with the people living everyday with diabetes and our desire to make their lives simpler and less burdensome. That core belief continues to guide our work every day.
0 · Reply
Skerk
Skerk Jun. 26 at 3:42 PM
$GCTK is this going to delist and go OTC? Can they even do another r/s?
0 · Reply
Glucotrack_IR
Glucotrack_IR Jun. 25 at 4:40 PM
$GCTK Behind every advancement in diabetes technology is a simple goal: helping people better manage their condition. People living with diabetes make decisions every day based on glucose information. We believe there remains an opportunity to expand how that information is collected and managed, thus simplifying the everyday management of diabetes. That belief is what moves us: By pursuing a new approach to glucose monitoring, we are working toward a future where innovation continues to push the boundaries of what is possible in diabetes care. Technology alone is not the goal. Creating new possibilities for people living with diabetes is.
0 · Reply
Latest News on GCTK
GlucoTrack Proxy statement: Proxy filing

Jun 17, 2026, 8:00 AM EDT - 17 days ago

GlucoTrack Proxy statement: Proxy filing


GlucoTrack Quarterly report: Q1 2026

May 14, 2026, 7:00 AM EDT - 7 weeks ago

GlucoTrack Quarterly report: Q1 2026


GlucoTrack Earnings release: Q1 2026

May 14, 2026, 7:00 AM EDT - 7 weeks ago

GlucoTrack Earnings release: Q1 2026


GlucoTrack Slides: Investor presentation

May 5, 2026, 7:00 AM EDT - 2 months ago

GlucoTrack Slides: Investor presentation


GlucoTrack Earnings release: Q4 2025

Mar 30, 2026, 7:00 AM EDT - 3 months ago

GlucoTrack Earnings release: Q4 2025


GlucoTrack Annual report: Q4 2025

Mar 30, 2026, 7:00 AM EDT - 3 months ago

GlucoTrack Annual report: Q4 2025


Why is Glucotrack Stock (GCTK) Up Nearly 30% Today?

2026-03-27T13:29:54.000Z - 3 months ago

Why is Glucotrack Stock (GCTK) Up Nearly 30% Today?


GlucoTrack Transcript: EGM 2026

Mar 12, 2026, 11:00 AM EDT - 4 months ago

GlucoTrack Transcript: EGM 2026


Glucotrack to Present at LSI USA '26 Medtech Innovation Summit

Mar 10, 2026, 8:01 AM EDT - 4 months ago

Glucotrack to Present at LSI USA '26 Medtech Innovation Summit


GlucoTrack Proxy statement: Proxy Filing

Feb 9, 2026, 7:00 AM EST - 5 months ago

GlucoTrack Proxy statement: Proxy Filing


GlucoTrack Proxy statement: Proxy Filing

Jan 29, 2026, 7:00 AM EST - 5 months ago

GlucoTrack Proxy statement: Proxy Filing


GlucoTrack Registration statement: Registration Filing

Jan 13, 2026, 7:00 AM EST - 6 months ago

GlucoTrack Registration statement: Registration Filing


GlucoTrack prices 1.03M shares at $3.87 in private placement

2025-12-30T13:05:37.000Z - 6 months ago

GlucoTrack prices 1.03M shares at $3.87 in private placement


GlucoTrack Earnings release: Q3 2025

Nov 13, 2025, 7:00 AM EST - 8 months ago

GlucoTrack Earnings release: Q3 2025


GlucoTrack Quarterly report: Q3 2025

Nov 13, 2025, 7:00 AM EST - 8 months ago

GlucoTrack Quarterly report: Q3 2025


GlucoTrack Transcript: AGM 2025

Nov 7, 2025, 12:00 PM EST - 8 months ago

GlucoTrack Transcript: AGM 2025


GlucoTrack Proxy statement: Proxy Filing

Nov 7, 2025, 7:00 AM EST - 8 months ago

GlucoTrack Proxy statement: Proxy Filing


Glucotrack, Inc. Encourages Shareholders to Vote

Nov 3, 2025, 4:05 PM EST - 8 months ago

Glucotrack, Inc. Encourages Shareholders to Vote


GlucoTrack Proxy statement: Proxy Filing

Nov 3, 2025, 7:00 AM EST - 8 months ago

GlucoTrack Proxy statement: Proxy Filing


GlucoTrack Proxy statement: Proxy Filing

Oct 31, 2025, 8:00 AM EDT - 8 months ago

GlucoTrack Proxy statement: Proxy Filing


GlucoTrack Inc trading resumes

2025-10-29T13:41:17.000Z - 8 months ago

GlucoTrack Inc trading resumes


GlucoTrack Inc trading halted, volatility trading pause

2025-10-29T13:36:24.000Z - 8 months ago

GlucoTrack Inc trading halted, volatility trading pause


Glucotrack, Inc. Reminds Shareholders to Vote

Oct 28, 2025, 8:00 AM EDT - 8 months ago

Glucotrack, Inc. Reminds Shareholders to Vote


GlucoTrack Proxy statement: Proxy Filing

Oct 28, 2025, 8:00 AM EDT - 8 months ago

GlucoTrack Proxy statement: Proxy Filing


GlucoTrack Proxy statement: Proxy Filing

Oct 15, 2025, 8:00 AM EDT - 9 months ago

GlucoTrack Proxy statement: Proxy Filing


GlucoTrack Registration statement: Registration Filing

Oct 8, 2025, 8:00 AM EDT - 9 months ago

GlucoTrack Registration statement: Registration Filing


GlucoTrack Proxy statement: Proxy Filing

Oct 3, 2025, 8:00 AM EDT - 9 months ago

GlucoTrack Proxy statement: Proxy Filing


GlucoTrack Registration statement: Registration Filing

Sep 29, 2025, 8:00 AM EDT - 9 months ago

GlucoTrack Registration statement: Registration Filing


GlucoTrack Proxy statement: Proxy Filing

Sep 23, 2025, 8:00 AM EDT - 10 months ago

GlucoTrack Proxy statement: Proxy Filing


Why Is Glucotrack Stock (GCTK) Up 150% Today?

2025-09-12T12:28:44.000Z - 10 months ago

Why Is Glucotrack Stock (GCTK) Up 150% Today?


Glucotrack to Participate in the Q3 Virtual Investor Summit

Sep 11, 2025, 8:00 AM EDT - 10 months ago

Glucotrack to Participate in the Q3 Virtual Investor Summit


GlucoTrack Earnings release: Q2 2025

Aug 14, 2025, 7:00 AM EDT - 11 months ago

GlucoTrack Earnings release: Q2 2025


GlucoTrack Quarterly report: Q2 2025

Aug 14, 2025, 7:00 AM EDT - 11 months ago

GlucoTrack Quarterly report: Q2 2025


GlucoTrack appoints David Hirsh as medical director, cardiology

2025-08-06T12:40:37.000Z - 11 months ago

GlucoTrack appoints David Hirsh as medical director, cardiology


GlucoTrack to exhibit at ADCES Annual Meeting

2025-07-31T12:35:20.000Z - 1 year ago

GlucoTrack to exhibit at ADCES Annual Meeting


GlucoTrack announces repurchase of Series A warrants

2025-07-08T12:41:19.000Z - 1 year ago

GlucoTrack announces repurchase of Series A warrants


Glucotrack Announces Repurchase of Series A Warrants

Jul 8, 2025, 8:30 AM EDT - 1 year ago

Glucotrack Announces Repurchase of Series A Warrants


GlucoTrack Inc trading resumes

2025-06-25T13:45:13.000Z - 1 year ago

GlucoTrack Inc trading resumes


GlucoTrack Quarterly report: Q1 2025

May 14, 2025, 4:00 PM EDT - 1 year ago

GlucoTrack Quarterly report: Q1 2025


GlucoTrack Earnings release: Q1 2025

May 14, 2025, 4:00 PM EDT - 1 year ago

GlucoTrack Earnings release: Q1 2025


GlucoTrack Proxy statement: Proxy Filing

Apr 28, 2025, 8:00 AM EDT - 1 year ago

GlucoTrack Proxy statement: Proxy Filing


GlucoTrack Proxy statement: Proxy Filing

Apr 18, 2025, 8:00 AM EDT - 1 year ago

GlucoTrack Proxy statement: Proxy Filing


GlucoTrack Annual report: Q4 2024

Mar 31, 2025, 5:00 PM EDT - 1 year ago

GlucoTrack Annual report: Q4 2024


GlucoTrack Earnings release: Q4 2024

Mar 31, 2025, 5:00 PM EDT - 1 year ago

GlucoTrack Earnings release: Q4 2024


Glucotrack Announces ISO 13485:2016 Certification

Jan 21, 2025, 8:01 AM EST - 1 year ago

Glucotrack Announces ISO 13485:2016 Certification


Glucotrack to Present at TechBio Showcase™ 2025

Jan 7, 2025, 4:05 PM EST - 1 year ago

Glucotrack to Present at TechBio Showcase™ 2025


GlucoTrack Proxy statement: Proxy Filing

Dec 6, 2024, 7:00 AM EST - 1 year ago

GlucoTrack Proxy statement: Proxy Filing


GlucoTrack Proxy statement: Proxy Filing

Nov 22, 2024, 7:00 AM EST - 1 year ago

GlucoTrack Proxy statement: Proxy Filing


GlucoTrack Quarterly report: Q3 2024

Nov 14, 2024, 7:00 AM EST - 1 year ago

GlucoTrack Quarterly report: Q3 2024


GlucoTrack Registration statement: Registration Filing

Nov 8, 2024, 7:00 AM EST - 1 year ago

GlucoTrack Registration statement: Registration Filing


GlucoTrack Registration statement: Registration Filing

Nov 8, 2024, 7:00 AM EST - 1 year ago

GlucoTrack Registration statement: Registration Filing


GlucoTrack Registration statement: Registration Filing

Nov 4, 2024, 7:00 AM EST - 1 year ago

GlucoTrack Registration statement: Registration Filing


GlucoTrack Registration statement: Registration Filing

Oct 24, 2024, 8:00 AM EDT - 1 year ago

GlucoTrack Registration statement: Registration Filing


GLUCOTRACK TO PRESENT AT 2024 BIOFUTURE CONFERENCE

Oct 22, 2024, 9:00 AM EDT - 1 year ago

GLUCOTRACK TO PRESENT AT 2024 BIOFUTURE CONFERENCE


GlucoTrack Registration statement: Registration Filing

Sep 30, 2024, 8:00 AM EDT - 1 year ago

GlucoTrack Registration statement: Registration Filing


GlucoTrack Registration statement: Registration Filing

Sep 23, 2024, 8:00 AM EDT - 1 year ago

GlucoTrack Registration statement: Registration Filing


GlucoTrack Registration statement: Registration Filing

Sep 16, 2024, 8:00 AM EDT - 1 year ago

GlucoTrack Registration statement: Registration Filing


GlucoTrack Proxy statement: Proxy Filing

Aug 19, 2024, 8:00 AM EDT - 2 years ago

GlucoTrack Proxy statement: Proxy Filing


GlucoTrack Quarterly report: Q2 2024

Aug 13, 2024, 8:00 AM EDT - 2 years ago

GlucoTrack Quarterly report: Q2 2024


GlucoTrack Proxy statement: Proxy Filing

Aug 9, 2024, 8:00 AM EDT - 2 years ago

GlucoTrack Proxy statement: Proxy Filing


GLUCOTRACK ANNOUNCES REVERSE STOCK SPLIT

May 15, 2024, 4:15 PM EDT - 2 years ago

GLUCOTRACK ANNOUNCES REVERSE STOCK SPLIT


CallMeMyBeer
CallMeMyBeer Jul. 4 at 2:58 AM
0 · Reply
Luckyizme
Luckyizme Jul. 2 at 12:09 AM
$GCTK This is due for another big runup. This week runners, $INO, $VTGN, $PCSA
1 · Reply
MarketsParadise
MarketsParadise Jul. 1 at 8:23 PM
Small caps heating up, We are seeing some big runners lately. Take a look at ticker DRCT 💎 I believe this is the next monster runner waiting to be found: DRCT 💎 • 600K share float! • AI-powered digital advertising & marketing drive. • Extremely thin chart. • Any sustained buying pressure we look for the 5$+. $GCTK $WCT.X $WHLR $ADTX ..22
0 · Reply
tartanurchin
tartanurchin Jul. 1 at 7:50 PM
$GCTK warming up???
0 · Reply
Glucotrack_IR
Glucotrack_IR Jul. 1 at 2:49 PM
$GCTK For decades, blood glucose monitoring (BGM) has helped people with diabetes understand their glucose levels through measurements taken at specific moments in time. At the same time, diabetes technology has advanced through different approaches to continuous glucose monitoring. Yet, one question remains: what if the continuity of modern monitoring could be combined with direct blood glucose measurement? That is the idea behind our Continuous Blood Glucose Monitoring (CBGM) technology. Rather than simply improving an existing approach, we are developing a novel system designed to bring together the benefits of continuous monitoring with direct blood glucose measurement, while also addressing the limitations associated with current wearable technologies. Innovation is often driven by challenging assumptions and exploring new possibilities. That is what excites us most about CBGM and its potential to help shape the next evolution of glucose monitoring.
0 · Reply
topstockalerts
topstockalerts Jul. 1 at 11:10 AM
Pre Market Top Gainers PT2 $LGPS $LGO $CEPO $FEAM $GCTK
0 · Reply
Deerslayer1998
Deerslayer1998 Jun. 30 at 6:16 AM
$GCTK so sad. A great product needed and no real news on these seminars. Guess people aren’t liking what they are seeing. I still believe in product but not management
1 · Reply
Glucotrack_IR
Glucotrack_IR Jun. 29 at 2:12 PM
$GCTK Diabetes affects roughly 1 in every 9 adults globally, including more than 38 million people in the United States alone, making it one of the most significant and widespread healthcare challenges of our time. Regardless of treatment strategy, medication, or insulin regimen, diabetes therapy often begins with one thing: understanding glucose levels. The information generated through glucose monitoring helps guide countless decisions made by people living with diabetes and healthcare providers every day. As a result, advances in how glucose is monitored measured have the potential to shape the broader standard of care. Meaningful advances begin with the people living everyday with diabetes and our desire to make their lives simpler and less burdensome. That core belief continues to guide our work every day.
0 · Reply
Skerk
Skerk Jun. 26 at 3:42 PM
$GCTK is this going to delist and go OTC? Can they even do another r/s?
0 · Reply
Glucotrack_IR
Glucotrack_IR Jun. 25 at 4:40 PM
$GCTK Behind every advancement in diabetes technology is a simple goal: helping people better manage their condition. People living with diabetes make decisions every day based on glucose information. We believe there remains an opportunity to expand how that information is collected and managed, thus simplifying the everyday management of diabetes. That belief is what moves us: By pursuing a new approach to glucose monitoring, we are working toward a future where innovation continues to push the boundaries of what is possible in diabetes care. Technology alone is not the goal. Creating new possibilities for people living with diabetes is.
0 · Reply
willopond210
willopond210 Jun. 24 at 5:58 PM
$GCTK I’m out. Total lack of transparency.
1 · Reply
willopond210
willopond210 Jun. 24 at 5:24 PM
$GCTK @Glucotrack_IR hearing rumors that the FDA denied your IDE.
0 · Reply
willopond210
willopond210 Jun. 24 at 12:27 PM
$GCTK @Glucotrack_IR your shareholders would appreciate a status update on the IDE and any other information. Thankyou
0 · Reply
Luckyizme
Luckyizme Jun. 24 at 11:27 AM
$GCTK UNCH ?
0 · Reply
willopond210
willopond210 Jun. 23 at 8:02 PM
$GCTK going up in AH.
0 · Reply
Jjoulez89
Jjoulez89 Jun. 19 at 12:42 AM
$GCTK Jumped in and bought some, see how it goes :)
1 · Reply
willopond210
willopond210 Jun. 18 at 10:53 PM
$GCTK I have two AH buys in and slapped the ask. Not going thru??
1 · Reply
Glucotrack_IR
Glucotrack_IR Jun. 18 at 9:08 PM
$GCTK CBGM represents a new modality in glucose monitoring, and ongoing engagement with the FDA remains an important part of advancing the program. As previously communicated, we continue working toward regulatory alignment while progressing preparations for the planned clinical study and look forward to providing a further update on our progress in Q3. We want to keep shareholders informed as key development and regulatory milestones are reached, and we intend to continue sharing updates as progress is made.
1 · Reply
Glucotrack_IR
Glucotrack_IR Jun. 18 at 9:06 PM
$GCTK Hi there! One of the objectives of this account is to provide shareholders with direct updates regarding the company’s progress and key milestones. We look forward to continuing that communication as the CBGM program advances and additional developments become available.
0 · Reply
Glucotrack_IR
Glucotrack_IR Jun. 18 at 9:05 PM
$GCTK Thanks for the support. We view this account as a channel for sharing information and staying connected with our shareholder community. We intend to remain active here and will continue providing updates as they become available. We appreciate the engagement and look forward to keeping the conversation going as progress continues.
0 · Reply
Glucotrack_IR
Glucotrack_IR Jun. 18 at 9:02 PM
$GCTK We understand the interest in this topic and appreciate the question. As an official company account, we can only comment on information that has been publicly disclosed. Please know that we continue to actively work on our regulatory and compliance initiatives, as soon as there is information that can be publicly shared, we will communicate it. We remain committed to keeping shareholders informed of material developments as they become available.
0 · Reply
willopond210
willopond210 Jun. 18 at 4:44 PM
$GCTK borrow rate still crazy high. I’m stacking my nuts. “The likelihood of Glucotrack, Inc. (Nasdaq: GCTK) getting its Investigational Device Exemption (IDE) application approved by the FDA is generally considered highly probable. Historically, over 70% of IDE studies for medical devices are fully approved within just two review cycles…”
0 · Reply